Teva Pharmaceutical Industries Financial Statements (TEVA)
|
|
|
|
Report date
|
|
|
21.02.2020 |
10.02.2021 |
09.02.2022 |
10.02.2023 |
12.02.2024 |
|
06.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
16 887 |
16 658 |
15 878 |
14 925 |
15 846 |
|
16 783 |
|
Operating Income, bln rub |
|
|
2 797 |
3 053 |
3 198 |
2 797 |
433.0 |
|
2 141 |
|
EBITDA, bln rub |
? |
|
1 279 |
-2 094 |
4 409 |
-874.0 |
4 333 |
|
2 025 |
|
Net profit, bln rub |
? |
|
-999.0 |
-3 990 |
417.0 |
-2 353 |
-559.0 |
|
-992.0 |
|
|
OCF, bln rub |
? |
|
538.0 |
1 216 |
798.0 |
1 590 |
1 368 |
|
2 468 |
|
CAPEX, bln rub |
? |
|
119.0 |
578.0 |
562.0 |
548.0 |
526.0 |
|
488.0 |
|
FCF, bln rub |
? |
|
419.0 |
638.0 |
236.0 |
1 042 |
842.0 |
|
1 980 |
|
Dividend payout, bln rub
|
|
|
52.0 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
4 816 |
4 668 |
4 495 |
4 283 |
4 451 |
|
4 629 |
|
Cost of production, bln rub |
|
|
9 351 |
8 933 |
8 284 |
7 952 |
8 200 |
|
8 413 |
|
R&D, bln rub |
|
|
1 010 |
997.0 |
967.0 |
838.0 |
953.0 |
|
978.0 |
|
Interest expenses, bln rub |
|
|
822.0 |
963.0 |
1 058 |
966.0 |
1 029 |
|
1 023 |
|
|
Assets, bln rub |
|
|
57 470 |
50 640 |
47 666 |
44 006 |
43 479 |
|
41 758 |
|
Net Assets, bln rub |
? |
|
13 972 |
10 026 |
10 278 |
7 897 |
7 506 |
|
6 065 |
|
Debt, bln rub |
|
|
27 342 |
26 398 |
23 459 |
21 561 |
20 153 |
|
19 275 |
|
Cash, bln rub |
|
|
1 975 |
2 177 |
2 165 |
2 801 |
3 226 |
|
3 319 |
|
Net debt, bln rub |
|
|
25 367 |
24 221 |
21 294 |
18 760 |
16 927 |
|
15 956 |
|
|
Ordinary share price, rub |
|
|
9.80 |
9.65 |
8.01 |
9.12 |
10.4 |
|
10.3 |
|
Number of ordinary shares, mln |
|
|
1 091 |
1 095 |
1 102 |
1 110 |
1 119 |
|
1 133 |
|
|
Market cap, bln rub |
|
|
10 692 |
10 567 |
8 827 |
10 123 |
11 682 |
|
11 670 |
|
EV, bln rub |
? |
|
36 059 |
34 788 |
30 121 |
28 883 |
28 609 |
|
27 626 |
|
Book value, bln rub |
|
|
-22 106 |
-19 521 |
-17 228 |
-16 006 |
-15 058 |
|
-14 815 |
|
|
EPS, rub |
? |
|
-0.92 |
-3.64 |
0.38 |
-2.12 |
-0.50 |
|
-0.88 |
|
FCF/share, rub |
|
|
0.38 |
0.58 |
0.21 |
0.94 |
0.75 |
|
1.75 |
|
BV/share, rub |
|
|
-20.3 |
-17.8 |
-15.6 |
-14.4 |
-13.5 |
|
-13.1 |
|
|
EBITDA margin, % |
? |
|
7.57% |
-12.6% |
27.8% |
-5.86% |
27.3% |
|
12.1% |
|
Net margin, % |
? |
|
-5.92% |
-24.0% |
2.63% |
-15.8% |
-3.53% |
|
-5.91% |
|
FCF yield, % |
? |
|
3.92% |
6.04% |
2.67% |
10.3% |
7.21% |
|
17.0% |
|
ROE, % |
? |
|
-7.15% |
-39.8% |
4.06% |
-29.8% |
-7.45% |
|
-16.4% |
|
ROA, % |
? |
|
-1.74% |
-7.88% |
0.87% |
-5.35% |
-1.29% |
|
-2.38% |
|
|
P/E |
? |
|
-10.7 |
-2.65 |
21.2 |
-4.30 |
-20.9 |
|
-11.8 |
|
P/FCF |
|
|
25.5 |
16.6 |
37.4 |
9.72 |
13.9 |
|
5.89 |
|
P/S |
? |
|
0.63 |
0.63 |
0.56 |
0.68 |
0.74 |
|
0.70 |
|
P/BV |
? |
|
-0.48 |
-0.54 |
-0.51 |
-0.63 |
-0.78 |
|
-0.79 |
|
EV/EBITDA |
? |
|
28.2 |
-16.6 |
6.83 |
-33.0 |
6.60 |
|
13.6 |
|
Debt/EBITDA |
|
|
19.8 |
-11.6 |
4.83 |
-21.5 |
3.91 |
|
7.88 |
|
|
R&D/CAPEX, % |
|
|
848.7% |
172.5% |
172.1% |
152.9% |
181.2% |
|
200.4% |
|
|
CAPEX/Revenue, % |
|
|
0.70% |
3.47% |
3.54% |
3.67% |
3.32% |
|
2.91% |
|
| Teva Pharmaceutical Industries shareholders |
